BioNTech is entering a period that will test whether its post-Covid identity can stand apart from the founders who built it. Ugur Sahin and Özlem Türeci are set to leave their executive roles by the end of 2026, and they plan to launch a separate mRNA venture — one in which BioNTech itself will take a minority stake in exchange for licensing rights and technology. The handover comes just as the company pushes toward its first-ever cancer drug approval.
The stock is treading water near 81.65 euros, up a marginal 0.37% from the prior session but still nursing a 10.47% loss over the past twelve months. From its January 52-week peak of 105.80 euros, the share price sits roughly 23% lower. That gap reflects a market increasingly focused on risk rather than promise.
BioNTech recently wrapped up a €1 billion share buyback program that had run since June, a move typically interpreted as management’s confidence in its own valuation. Yet the buyback’s impact has been overshadowed by a more pressing question: who will take the helm after Sahin and Türeci? The supervisory board is actively searching for successors, aiming for a seamless transition that does not derail the company’s oncology strategy.
On the clinical front, the pipeline is brimming with potential catalysts. By year-end, BioNTech expects to have 15 Phase 3 studies underway in oncology, with several late-stage data readouts slated for 2026. The company has already kicked off five additional registration-enabling trials for Pumitamig — its lead bispecific antibody — in partnership with Bristol Myers Squibb. Another collaboration with Boehringer Ingelheim added a new combination study testing Pumitamig alongside Obrixtamig in advanced small-cell lung cancer.
The ASCO annual meeting in late May was expected to provide Phase 2 results from the ROSETTA-Lung-02 trial, evaluating Pumitamig in non-small cell lung cancer. Meanwhile, the most concrete near-term milestone is a regulatory filing for Trastuzumab Pamirtecan, an antibody-drug conjugate developed with DualityBio. Fast-track designations from the FDA are already in hand, and the submission — BioNTech’s first cancer approval application ever — is planned for later this year, backed by strong Phase 2 response rates.
Should investors sell immediately? Or is it worth buying BioNTech?
Financially, the shift away from Covid vaccine revenue is stark. First-quarter 2026 revenue came in at just 118.1 million euros, while research spending hit 557 million euros. The bottom line swung to a net loss of 531.9 million euros, and management has said it does not expect any oncology product revenue this year. Still, a cash reserve of roughly €17.2 billion at the end of 2025 provides ample runway to fund the pipeline through the high-burn phase. BioNTech has guided for full-year 2026 revenue of up to 2.3 billion euros.
Opinion on the stock is split. Citi analysts praise the quality of the clinical data and see the average price target of 106.86 euros — representing about 31% upside — as achievable. Bernstein takes a more cautious view, noting that the bispecific antibody class has historically struggled to show statistically significant survival benefits. The firm estimates peak pipeline sales roughly 43% below the consensus, and warns that negative Phase 3 results for Pumitamig could seriously dent investor confidence.
Technically, the stock has stabilized just above its 50-day moving average of 80.30 euros, a level that offers near-term support. The 200-day average at 85.35 euros remains out of reach, signaling that the broader trend has yet to turn convincingly bullish.
The next formal update comes on August 4, when BioNTech reports second-quarter results and provides a pipeline progress report. But the real focus is on the wave of late-stage data due over the coming months. A single positive readout could quickly erase the valuation discount. A disappointed the first major Phase 3 outcome could amplify the bears’ case. What happens next will define whether BioNTech can step out of its founders’ shadow and into a new era as a commercial oncology player.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from July 1 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from July 1.
BioNTech: Buy or sell? Read more here...
